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Practical Dosimetry of 131I in Patients with Thyroid
Carcinoma
James C. Sisson, M.D.
Division of Nuclear Medicine, Department of Radiology, University of Michigan Health System, Ann
Arbor, MI
Radioiodine treatments of patients with well-differentiated thyroid carcinoma have generally been safe
and beneficial. Safety can be ensured while efficacy is increased through practical methods of dosimetry
that measure body retention of 131I. Prescriptions for therapeutic 131I can be decreased when the reten-
tion level is high and increased when the level is low. Assays of serum free T4 will alert the physician to
possible increased radiation to blood and bone marrow, and appreciable concentrations of free T4 are
indications to reduce the therapeutic 131I. Carcinomas $1 cm in diameter that are not visible on diag-
nostic scintigraphy are unlikely to respond to the commonly prescribed mCi of 131I. Biologic responses
to commonly prescribed levels of therapeutic 131I, as seen in toxic changes of normal tissues and in in-
dices of tumor size, will be the final dosimeters. With lower levels of prescribed diagnostic 131I, stunning
should not impair dosimetry. Thus, readily obtained measurements make dosimetry a practical method
for improving carcinoma therapy with 131I.
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INTRODUCTION
Delivery of selective and tumoricidal radiation to
patients with carcinomas is a compelling concept.
Treatments of patients with thyroid carcinomas
have long been portrayed as examples of this con-
cept in practice. Yet, many well-differentiated
thyroid neoplasms in advanced stages have not
fully responded to therapies with 131I. Radiation
dosimetry has the potential of increasing the ef-
fectiveness of radioiodine treatments while pre-
venting or limiting toxicity to normal tissues.
Most of the energies from disintegrations of
131I are deposited within 1 mm from beta parti-
cles and therefore are largely confined to the car-
cinomas that concentrate the radionuclide. Nev-
ertheless, normal body structures must receive
some radiation from the 131I that diffuses through
the body before excretion, and large amounts of
radioiodine can damage organs and tissues. Years
ago, from observations of many patients treated
with 131I, Benua et al.1 developed guidelines
based on body retention of radioactivity and ab-
sorbed radiation to the blood (as a surrogate for
radiation to the bone marrow), to prevent toxicity
(Table 1). Thomas and colleagues reported that,
for most patients, the absorbed blood dose could
be inferred from the level of retention of 131I in
the body2 (Table 2), and it appeared that the frac-
tion of radioactivity remaining in a patient at 48
hours would serve as the guideline to prevent tox-
icity. Exceptions to the blood-body relationships3
will be discussed below.
Despite the advantages of dosimetry, it is not
commonly practiced in the care of patients with
thyroid carcinoma. Many physicians find dosime-
try methods daunting, and they know that the
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most often prescribed therapies of 131I, 3.7–7.4
GBq (100–200 mCi), are rarely followed by
marked toxicity in normal tissues. However, there
are a few patients who exhibit relatively high re-
tentions of 131I in their bodies that could not be
predicted by knowledge of renal function or of
the volumes of tumor. In such patients, 100–200
mCi may pose a risk to normal structures, espe-
cially if administered several times. Moreover, al-
though there are no data showing that multiple
administrations of moderate amounts of 131I are
not efficacious, it would seem that the initial
treatment with 131I is likely to have the greatest
effect on the carcinoma and, therefore, should be
substantial in amount yet still safe.
Measurements of radioactivity in the target tu-
mors would permit a refined dosimetry, but this
approach is difficult at best and often impossible
because tumor volumes cannot be determined ac-
curately. Still, judgments can be made on the fu-
tility of radiopharmaceutical therapy when there
is absence of 131I uptake in tumors that are visi-
ble by radiographs or by clinical examination.
Thus, dosimetry in patients with well-differen-
tiated thyroid carcinomas can provide informa-
tion: 1) to ensure safety in normal tissues, 2) to
increase efficacy of tumor treatment and 3) to
identify futility of 131I therapy for carcinomas in
some patients. This report will describe how read-
ily obtained information on dosimetry can use-
fully guide prescriptions of 131I for treatment of
patients with thyroid carcinomas.
RECOMMENDATIONS FOR 
PRACTICAL DOSIMETRY
Measuring Retention of 131I in the Body
Assays of retention can be readily made in any
nuclear medicine laboratory. Patients are seated
on a stool 2.5 m from a standard uptake probe
aimed at the xiphoid. Determination of a flat field
response of the probe will ensure accuracy. An-
terior and posterior counts are obtained for 2 min-
utes each from the seated patient, and appropri-
ate background is subtracted. A geometric mean
is calculated for a 100% value 2 hours after in-
gestion of 131I, and the relative retention is de-
termined 2 days later.
Measurements made in over 80 patients dem-
onstrated that retentions of 131I at 2 days (ap-
proximately 48 hours) exhibited a broad range:
,5% to 50% of the administered radioactivity
(unpublished data). A large proportion of patients
fell in the range of 10–25%. A reasonable corre-
lation between retention of diagnostic and of ther-
apeutic 131I was found.
Many physicians will not feel comfortable ad-
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ministering therapeutic quantities of 131I that ap-
proach the induction of toxicity, but even with
relatively safe amounts of 131I, prescriptions can
be modified to increase efficacy. For example, a
retention below 10% would be an indication to
increase their usual prescription of 131I. On the
other hand, a retention may be greater than 25%,
and the usual prescription could then be de-
creased to ensure safety.
Estimating Increased Blood Concentrations
of 131I
As noted above and in Table 2, for most patients
the absorbed radiation to blood can be inferred
from the body retention of 131I, and therefore ra-
dioactivity in blood will not modify the amount
of therapeutic 131I determined from body reten-
tion. However, in a few patients, the carcinomas
synthesize compounds that will become labeled
with the administered 131I.4 Some of these or-
ganic molecules, particularly thyroxine, will cir-
culate for days5 in contrast to radioiodide that
rapidly disappears from the blood. In these cir-
cumstances the bone marrow receives a dispro-
portionately high level of radiation. Although
dosimetry of blood can give an estimate of ab-
sorbed radiation, measurements must be carried
out for many days and errors can still be appre-
ciable.3
A clue to the possibility of increased blood ra-
diation is found in the concentration of serum thy-
roxine measured in the absence of thyroid hor-
mone medication and usually expressed as free
T4 (fT4). With fT4 concentrations ,0.25 ng/dl
there should be inappreciable levels of 131I la-
beled compounds that circulate with half-lives
longer than a day, but higher concentrations of
fT4 should signal caution. After the body reten-
tion at 2 days has been determined, therapeutic
131I will be prescribed, but this amount of 131I
may be modified using the fT4 value as a guide.
Reduce 131I in the treatment by:
10–20% for 0.25–1.0 ng/dl,
20–40% for 1.0–1.8 ng/dl, and
40–60% for .1.8 ng/dl of fT4.
Tumor Dosimetry and the Limitations of
Therapy for Carcinoma
Maxon et al. determined that 8000 rad (cGy),6
and preferably 14000 rad,7 from 131I treatments
were necessary to reduce cervical node metas-
tases of well-differentiated thyroid carcinoma to
scintigraphic invisibility; when the absorbed dose
of radiation was ,4000 rad, none of the metas-
tases disappeared.8 Such measurements are diffi-
cult and often impossible to perform. Still, the re-
sults give an indication of levels of radiation that
are ineffective.
Although well-differentiated carcinomas con-
centrate 131I to varying levels, a relationship be-
tween scintigraphic visibility of tumors and ef-
fective therapy has been worked out in laboratory
experiments with phantoms.9 In a mock tumor of
300 ml, 0.3 mCi of 131I could be detected by a
gamma camera in a background of radioactivity
simulating that in a patient. Assuming that same
concentration of activity would be detectable in
a 1000 ml mock, i.e., 1 mCi/ml, then the total in
this larger mock would be 0.05% of 2 mCi of 131I
administered for diagnosis. From 0.05% of 200
mCi given for therapy, the concentration would
be 100 mCi/ml, and, with an effective half life of
3 days that is commonly seen in thyroid carci-
nomas,6 the absorbed radiation in this 1 ml tar-
get would be approximately 4500–5000 rad.
Thus, a tumor of 1 ml (spherical diameter 1.25
cm) that is invisible to scintigraphy after 2 mCi
of 131I would concentrate ,0.0005 of adminis-
tered 131I and receive less than 4500 rad from 200
mCi. Probably more modern cameras could de-
tect even smaller concentrations of radioactivity,
especially in the low background activity of
lungs. Therefore, thyroid carcinomas that are 1
cm and larger by radiographic or clinical mea-
surements but undetectable by a gamma camera
would not be eliminated by therapeutic 131I in the
range of 200 mCi. Such treatments are likely to
be futile.
Biological Responses as Indices of 
Radiation Effects
Ultimately, the responses of tumors and normal
tissues will determine the efficacy and toxicity of
131I therapies. The goals of treatment should be
determined beforehand, including not only the
scintigraphic changes but also those in clinical,
radiographic and biochemical (serum thyroglob-
ulin) expressions of the carcinomas. Progressive
disease, especially within the first 6–12 months
after therapy is an indicator of failure. Samaan 
et al. found that most of the benefits in their pa-
tients were seen after the first 300 mCi of 131I
were given.10
The guidelines (Table 1) have served well to
prevent major toxicity.11–13 Still, depression of
bone marrow function is a major concern. Cy-
togenetic analysis of lymphocytes after treat-
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ments is a sophisticated assessment of radiation
effects14,15 but not practical in most clinics. How-
ever, for patients who are to receive larger and
repeated administrations of 131I, it is wise to have
a hemogram of platelets, leukocytes and hemo-
globin before a treatment and 5–6 weeks later. A
major decline in one or more of these blood ele-
ments, even though temporary, would signal sub-
stantial effects on marrow function. Since radia-
tion effects on tissues are cumulative, future
treatments may induce more marked toxicity.
Salivary and lacrimal gland dysfunction arises
in 25% or more of patients receiving 100 mCi or
more of 131I, and chronic xerostomia will afflict
a substantial number.16,17 It is not clear whether
techniques that increase saliva flow, as from
chewing gum, lessen these effects, but they are
worth considering. Thus, before administering
additional 131I, account should be taken of sali-
vary and lacrimal gland responses, at least in
terms of symptoms, to prior therapy, and efforts
should be made to minimize future impairments.
DRAWBACK TO DOSIMETRY: 
POSSIBLE STUNNNG
Stunning of thyroid tissues, carcinoma and resid-
ual normal gland, is the decrease in concentration
of therapeutic 131I in these tissues as a conse-
quence of the effects of a preceding administra-
tion of 2–10 mCi of diagnostic 131I. The evidence
for this effect has been: changes in target-to-back-
ground patterns on scintigraphic images,18–21
quantitative decreases in fractional uptake of ra-
dioiodine by the tissues,20,22–24 and lesser re-
sponses to the therapies with 131I.25,26
To obviate what has been thought to be stun-
ning, 123I has been suggested as a substitute for
131I. Compared to 131I, less radiation per mCi will
be imparted by 123I, but diagnostic sensitivity for
tumors was less with 123I than with 131I.25 More-
over, dosimetry is difficult to perform with the
rapidly disappearing (half life 13 h) 123I.
Although fractional concentrations of thera-
peutic 131I have been found to be smaller than
those of diagnostic 131I at the same time points,
it is not clear whether this difference is related to
the early radiation effects from the diagnostic or
the therapeutic 131I. Probably there is little if any
radiation effect imparted by diagnostic 131I of 2
mCi27 and especially of 1 mCi. Sensitivity can
be preserved by increasing the time of data ac-
quisition after the smaller amounts of 131I. There-
fore, unless one is convinced that arbitrary
amounts of 131I are optimal for treatments of pa-
tients with thyroid carcinoma, the value of
dosimetry as described above would seem to out-
weigh any drawback of stunning.
CONCLUSIONS
The principles of radiation dosimetry have been
used to develop practical measurements in pa-
tients who are to be treated with 131I for well-dif-
ferentiated thyroid carcinoma.
The retention of radioiodine in a patient’s body
is readily assayed in a clinical nuclear medicine
laboratory. Based on the retention at 48 hours (2
days) a prescription for therapy with 131I can be
made that will be within the guidelines estab-
lished years ago to avoid toxicity. From knowl-
edge of the wide variation in retention of ra-
dioiodine among patients, a usual prescription for
therapeutic 131I can be modified to give more mCi
if retention is low, increasing efficacy, and fewer
mCi if retention is high, ensuring safety.
Absorbed radiation to blood has served to pre-
dict bone marrow depression from 131I. In most
patients, radiation of blood is correlated with the
retention in the body. Cognizance of the free thy-
roxine concentration will enable modification of
the prescription of 131I to keep treatments within
the established guidelines for safety.
When carcinomas are 1 cm and larger in di-
ameter but are not visible on scintigraphic image,
it is unlikely that the usual amounts of therapeu-
tic 131I will impart effective radiation to the tu-
mors.
Biological responses are the final arbiters of
dosimetry. Changes in indices of tumor status—
clinical, scintigraphic, radiographic and serum
thyroglobulin—reflect efficacy. Post-therapy
concentrations of blood elements can portend
toxicity.
The lower amounts of diagnostic 131I are un-
likely to produce appreciable stunning of the thy-
roid carcinomas.
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